Overview

• Durvalumab, an immunotherapy drug already used for lung cancer, was shown to reduce the risk of bladder cancer progression or recurrence by 32%.
• The two-year survival rate for patients receiving durvalumab in combination with chemotherapy was 82.2%, compared to 75.2% for those receiving standard treatment.
• The study included 1,063 patients with advanced muscle-invasive bladder cancer and was conducted by researchers from the University of Sheffield and Queen Mary University of London.
• Experts described the findings as a 'major breakthrough,' with hopes that durvalumab will soon receive regulatory approval and become a new standard of care.
• Bladder cancer cases are projected to rise by 50% over the next two decades, underscoring the importance of advancing treatment options like durvalumab.